Literature DB >> 12682272

Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies.

Cyril J Cohen1, Offra Sarig, Yoshihisa Yamano, Utano Tomaru, Steven Jacobson, Yoram Reiter.   

Abstract

The advent in recent years of the application of tetrameric arrays of class I peptide-MHC complexes now enables us to detect and study rare populations of Ag-specific CD8(+) T cells. However, available methods cannot visualize or determine the number and distribution of these TCR ligands on individual cells nor detect APCs in tissues. In this study, we describe for the first time studies of human class I peptide-MHC ligand presentation. These studies were facilitated by applying novel tools in the form of peptide-specific, HLA-A2-restricted human recombinant Abs directed toward a viral epitope derived from human T cell lymphotropic virus type I. Using a large human Ab phage display library, we isolated a large panel of recombinant Fab Abs that are specific for a particular peptide-MHC class I complex in a peptide-dependent, MHC-restricted manner. We used these Abs to visualize the specific complex on APCs and virus-infected cells by flow cytometry, to quantify the number of, and visualize in situ, a particular complex on the surface of APCs bearing complexes formed by naturally occurring active intracellular processing of the cognate viral Ag. These findings demonstrate our ability to transform the unique fine specificity, but low intrinsic affinity of TCRs into high affinity soluble Ab molecules endowed with a TCR-like specificity toward human viral epitopes. These molecules may prove to be crucial useful tools for studying MHC class I Ag presentation in health and disease as well as for therapeutic purposes in cancer, infectious diseases, and autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682272     DOI: 10.4049/jimmunol.170.8.4349

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens.

Authors:  J M Boulter; B K Jakobsen
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

2.  Epitopes of the class I major histocompatibility complex (MHC-I) recognized in the syngeneic or allogeneic context predominantly linked to antigenic peptide loading to its binding groove.

Authors:  P Nguyen van Binh; H T Duc
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

3.  Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.

Authors:  Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Journal:  Mol Immunol       Date:  2006-12-12       Impact factor: 4.407

4.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers.

Authors:  Michal Bassani-Sternberg; Eilon Barnea; Ilan Beer; Irit Avivi; Tami Katz; Arie Admon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

5.  Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Authors:  Eynav Klechevsky; Michael Gallegos; Galit Denkberg; Karolina Palucka; Jacques Banchereau; Cyril Cohen; Yoram Reiter
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

6.  T Cell Receptor Engineering and Analysis Using the Yeast Display Platform.

Authors:  Sheena N Smith; Daniel T Harris; David M Kranz
Journal:  Methods Mol Biol       Date:  2015

Review 7.  TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells.

Authors:  Jon A Weidanz; Oriana Hawkins; Bhavna Verma; William H Hildebrand
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

8.  Relaxation Times of Ligand-Receptor Complex Formation Control T Cell Activation.

Authors:  Hamid Teimouri; Anatoly B Kolomeisky
Journal:  Biophys J       Date:  2020-06-09       Impact factor: 4.033

9.  TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.

Authors:  Mahiuddin Ahmed; Andres Lopez-Albaitero; Dmitry Pankov; Brian H Santich; Hong Liu; Su Yan; Jingyi Xiang; Pei Wang; Aisha N Hasan; Annamalai Selvakumar; Richard J O'Reilly; Cheng Liu; Nai-Kong V Cheung
Journal:  JCI Insight       Date:  2018-02-22

10.  Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late.

Authors:  Saghar Kaabinejadian; Curtis P McMurtrey; Sojung Kim; Rinki Jain; Wilfried Bardet; Fredda B Schafer; Jason L Davenport; Aaron D Martin; Michael S Diamond; Jon A Weidanz; Ted H Hansen; William H Hildebrand
Journal:  J Immunol       Date:  2016-04-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.